Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 352

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis

Open access
Ribassin-Majed, Laureen, Marguet, Sophie, Lee, Anne W.M., Ng, Wai Tong, Ma, Jun, Chan, Anthony T.C., Huang, Pei-Yu, Zhu, Guopei, Chua, Daniel T.T., Chen, Yong, Mai, Hai-Qiang, Kwong, Dora L.W., Cheah, Shie-Lee, Moon, James, Tung, Yuk, Chi, Kwan-Hwa, Fountzilas, George, Bourhis, Jean, Pignon, Jean Pierre, Blanchard, Pierre, on behalf of the Meta-Analysis of Chemotherapy in Nasopharyngeal Collaborative Group·2017·Journal of Clinical Oncology

Abstract

Purpose: The role of adjuvant chemotherapy (AC) or induction chemotherapy (IC) in the treatment of locally advanced nasopharyngeal carcinoma is controversial. The individual patient data from the Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma database were used to compare all available treatments. Methods: All randomized trials of radiotherapy (RT) with or without chemotherapy in nonmetastatic nasopharyngeal carcinoma were considered. Overall, 20 trials and 5,144 patients were included. Treatments were grouped into seven categories: RT alone (RT), IC followed by RT (IC-RT), RT followed by AC (RT-AC), IC followed by RT followed by AC (IC-RT-AC), concomitant chemoradiotherapy (CRT), IC followed by CRT (IC-CRT), and CRT followed by AC (CRT-AC). P-score was used to rank the treatments. Fixed- and random-effects frequentist network meta-analysis models were applied. Results: The three treatments with the highest probability of benefit on overall survival (OS) were CRT-AC, followed by CRT and IC-CRT, with respective hazard ratios (HRs [95% CIs]) compared with RT alone of 0.65 (0.56 to 0.75), 0.77 (0.64 to 0.92), and 0.81 (0.63 to 1.04). HRs (95% CIs) of CRT-AC compared with CRT for OS, progression-free survival (PFS), locoregional control, and distant control (DC) were, respectively, 0.85 (0.68 to 1.05), 0.81 (0.66 to 0.98), 0.70 (0.48 to 1.02), and 0.87 (0.61 to 1.25). IC-CRT ranked second for PFS and the best for DC. CRT never ranked first. HRs of CRT compared with IC-CRT for OS, PFS, locoregional control, and DC were, respectively, 0.95 (0.72 to 1.25), 1.13 (0.88 to 1.46), 1.05 (0.70 to 1.59), and 1.55 (0.94 to 2.56). Regimens with more chemotherapy were associated with increased risk of acute toxicity. Conclusion: The addition of AC to CRT achieved the highest survival benefit and consistent improvement for all end points. The addition of IC to CRT achieved the highest effect on DC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.67.4119

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 352

Metadata

Authors
Ribassin-Majed, L., Marguet, S., Lee, A. W. M., Ng, W. T., Ma, J., Chan, A. T. C., Huang, P.-Y., Zhu, G., Chua, D. T. T., Chen, Y., Mai, H.-Q., Kwong, D. L. W., Cheah, S.-L., Moon, J., Tung, Y., Chi, K.-H., Fountzilas, G., Bourhis, J., Pignon, J. P., Blanchard, P., & on behalf of the Meta-Analysis of Chemotherapy in Nasopharyngeal Collaborative Group
Venue
Journal of Clinical Oncology
Published
2017-02-10
Volume
35
Issue
5
Pages
498-505
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2559861554
Cited by
352
References
30
FWCI
30.82
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. https://app.cochat.ai/papers/10.1200/jco.2016.67.4119
The paper
Ribassin-Majed, L., Marguet, S., Lee, A. W. M., Ng, W. T., Ma, J., Chan, A. T. C., Huang, P.-Y., Zhu, G., Chua, D. T. T., Chen, Y., Mai, H.-Q., Kwong, D. L. W., Cheah, S.-L., Moon, J., Tung, Y., Chi, K.-H., Fountzilas, G., Bourhis, J., Pignon, J. P., . . . on behalf of the Meta-Analysis of Chemotherapy in Nasopharyngeal Collaborative Group. (2017). What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.67.4119

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.